Stock Analysis on Net
Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

Balance Sheet: Assets
Quarterly Data

Beginner level

The balance sheet provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Biogen Inc., consolidated balance sheet: assets (quarterly data)

US$ in thousands

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Cash and cash equivalents 2,384,900  2,591,300  2,913,700  2,343,900  1,723,400  2,243,200  1,224,600  2,386,700  1,250,200  4,108,000  1,573,800  1,548,100  1,169,500  924,000  2,326,500  2,084,800  1,362,000  1,130,700  1,308,000  4,089,003  1,282,078  1,478,051 
Marketable securities 1,942,700  1,269,100  1,562,200  2,093,500  1,228,800  1,665,800  2,313,400  2,041,700  1,974,000  1,808,000  2,115,200  1,960,200  1,723,500  1,956,200  2,568,600  2,231,200  2,434,800  2,454,700  2,120,500  1,753,499  1,086,595  673,946 
Accounts receivable, net 2,133,600  2,092,600  1,880,500  1,933,500  1,959,600  2,088,900  1,958,500  2,017,300  1,951,000  1,939,200  1,787,000  1,567,500  1,630,200  1,501,500  1,441,600  1,467,800  1,293,000  1,395,100  1,227,000  1,327,780  1,310,821  1,389,995 
Due from anti-CD20 therapeutic programs 441,100  511,600  590,200  582,300  557,500  527,100  526,900  508,400  481,900  553,500  532,600  518,000  502,900  324,500  300,600  305,200  334,100  315,100  314,500  319,788  323,714  311,956 
Inventory 952,700  858,800  804,200  751,800  776,700  770,200  929,900  916,600  931,700  890,800  902,700  1,007,200  936,500  921,600  1,001,600  1,009,700  996,400  964,600  893,400  918,921  865,738  825,349 
Assets held for sale —  —  —  —  683,400  682,000  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Other current assets 638,800  683,800  631,000  743,200  980,400  965,400  687,600  848,300  843,300  895,900  962,000  967,000  1,146,100  1,231,900  1,093,300  993,100  1,027,400  941,100  836,900  861,882  750,039  579,599 
Current assets 8,493,800  8,007,200  8,381,800  8,448,200  7,909,800  8,942,600  7,640,900  8,719,000  7,432,100  10,195,400  7,873,300  7,568,000  7,108,700  6,859,700  8,732,200  8,091,800  7,447,700  7,201,300  6,700,300  9,270,873  5,618,985  5,258,896 
Marketable securities 922,800  969,500  1,408,100  1,813,900  1,309,300  1,372,700  1,375,900  1,244,500  1,160,200  1,200,200  3,057,300  3,062,000  2,632,700  2,825,200  2,829,400  3,096,900  3,477,600  3,189,800  2,760,400  1,947,354  2,101,796  1,377,325 
Property, plant and equipment, net 3,330,700  3,281,600  3,247,300  3,138,100  3,077,500  3,013,800  3,601,200  3,538,900  3,409,000  3,334,700  3,182,400  2,995,900  2,827,600  2,610,900  2,501,800  2,387,000  2,301,800  2,258,900  2,187,600  2,027,821  1,837,670  1,739,628 
Operating lease assets 436,200  422,000  427,000  422,000  434,400  447,800  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Intangible assets, net 3,383,800  3,446,900  3,527,400  3,392,400  3,681,300  3,056,200  3,120,000  3,379,000  3,661,300  3,794,500  3,879,600  4,019,400  4,051,300  4,103,900  3,808,300  3,869,900  3,967,600  4,012,200  4,085,100  4,181,245  4,294,791  4,353,123 
Goodwill 5,751,000  5,752,000  5,757,800  5,746,100  5,749,200  5,639,700  5,706,400  5,440,100  5,170,300  4,907,800  4,632,500  4,127,500  3,870,400  3,611,700  3,669,300  3,419,700  3,167,100  2,917,900  2,663,800  2,408,854  2,154,341  1,849,852 
Deferred tax asset 1,710,200  3,109,400  3,232,100  3,284,500  2,820,100  2,074,400  2,153,900  2,160,900  2,217,900  2,277,400  595,900  —  —  —  —  —  —  —  —  —  —  — 
Investments and other assets 1,483,300  1,130,600  1,252,800  1,238,800  1,306,000  1,898,300  1,690,600  1,009,800  902,100  380,100  431,600  1,300,400  1,268,300  1,184,500  1,335,800  1,239,600  1,153,000  1,094,600  1,107,600  892,221  751,588  640,630 
Long-term assets 17,018,000  18,112,000  18,852,500  19,035,800  18,377,800  17,502,900  17,648,000  16,773,200  16,520,800  15,894,700  15,779,300  15,505,200  14,650,300  14,336,200  14,144,600  14,013,100  14,067,100  13,473,400  12,804,500  11,457,495  11,140,186  9,960,558 
Total assets 25,511,800  26,119,200  27,234,300  27,484,000  26,287,600  26,445,500  25,288,900  25,492,200  23,952,900  26,090,100  23,652,600  23,073,200  21,759,000  21,195,900  22,876,800  22,104,900  21,514,800  20,674,700  19,504,800  20,728,368  16,759,171  15,219,454 

Based on: 10-Q (filing date: 2020-07-22), 10-Q (filing date: 2020-04-23), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-22), 10-Q (filing date: 2019-07-24), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-06), 10-Q (filing date: 2018-10-23), 10-Q (filing date: 2018-07-24), 10-Q (filing date: 2018-04-24), 10-K (filing date: 2018-02-01), 10-Q (filing date: 2017-10-24), 10-Q (filing date: 2017-07-25), 10-Q (filing date: 2017-04-25), 10-K (filing date: 2017-02-02), 10-Q (filing date: 2016-10-26), 10-Q (filing date: 2016-07-21), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-03), 10-Q (filing date: 2015-10-21), 10-Q (filing date: 2015-07-24), 10-Q (filing date: 2015-04-24).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Biogen Inc.’s current assets decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
Property, plant and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Biogen Inc.’s property, plant and equipment, net increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Long-term assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Biogen Inc.’s long-term assets decreased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Biogen Inc.’s total assets decreased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Biogen Inc.’s cash and cash equivalents decreased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Marketable securities Amount of investment in marketable security, classified as current. Biogen Inc.’s marketable securities decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
Accounts receivable, net Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Biogen Inc.’s accounts receivable, net increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Inventory Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Biogen Inc.’s inventory increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.